AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03131219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing \< 20 kg.
Study NCT00979433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Description: Bubble CPAP will be delivered using Fischer \& Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
Study NCT00979433 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional CPAP
Description: Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
Study NCT04579965 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: medical treatment of isthmocele
Description: comparison between different drugs
Study NCT00412971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hexvix
Description: Single installation, TURB
Study NCT00412971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard white light cystoscopy
Study NCT02004548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metatinib Tromethamine
Study NCT03057808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestational weight gain intervention
Description: This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
Study NCT03057808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum weight loss intervention
Description: The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
Study NCT03935503 — intervention group
Intervention type: PROCEDURE
Intervention: TEP
Description: By making a 2 cm incision under the umbilicus, skin subcutaneous tissues are passed through blunt dissections and the anterior fascia of the rectus muscle is exposed. An anterior rectus sheath with a scalpel is performed with a 15 mm incision. The rectus muscle is laterally lateralized and the balloon trocar or laparoscope itself is advanced from the midline to the symphysis pubis via the posterior rectus sheath. After the peritoneal cavity is dissected, a low pressure pneumoperitone 10 mm Hasson trocar or another 10 mm balloon caged trocar is advanced through the subumblic incision. 9-11 mmHg low pressure pneumoperitoneum is created to prevent the development of subcutaneous emphysema. For proper imaging, the patient should have complete muscle relaxation. The patient is given a position towards the light trandelenburg and non-hernia side.
Study NCT03935503 — intervention group
Intervention type: PROCEDURE
Intervention: Lichtenstein repair
Description: After the inguinal incision, the skin and subcutaneous camper and scarpa tissues are passed and the external oblique aponeurosis is dissected in the direction of the extension of the fibers and the medial lateral edge of the rectus is dissected to the lateral inguinal ligament, then the spermatic cord is released and suspended.The spermatic cord is separated from the inguinal canal.~In indirect hernias, the hernia sac is dissected from the spermatic cord and rejected into the abdomen by high ligation. In direct hernia, the hernia sac is pushed in and the transverse fascia is sutured with 2-3 separe stitches.
Study NCT01520298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
Study NCT01520298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV
Description: For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
Study NCT02997371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra Prefilled Syringe
Description: Administration as initially intravenous injection followed by a intravenous infusion
Study NCT02997371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Placebo, administration as initially intravenous injection followed by a intravenous infusion
Study NCT04777526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception exercises
Description: Exercises for recognition of thumb position and thumb force sense.
Study NCT04777526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint protection program
Description: Reeducation in the activities daily life
Study NCT04777526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint protection program
Description: Reeducation in the activities daily life
Study NCT04777526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thumb orthosis
Description: Thumb night orthosis
Study NCT04777526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thumb orthosis
Description: Thumb night orthosis
Study NCT04777526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual distraction
Description: Manual distraction of CMC joint
Study NCT04777526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual distraction
Description: Manual distraction of CMC joint
Study NCT01012479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil and hydrochlorothiazide
Description: Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
Study NCT02918760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
Study NCT02918760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
Study NCT03613987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA technology to synchronize NIPPV
Description: Neurally adjust ventilator assist is used to synchronize the NIPPV
Study NCT02259907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL
Study NCT02259907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02259907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Study NCT04579601 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS program
Description: We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
Study NCT02240693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Study NCT02240693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02240693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03482583 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Replacement Therapy
Description: Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
Study NCT02220543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back on Track intervention
Description: Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
Study NCT02220543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back on Track intervention
Description: Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
Study NCT03482583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Referral to AHEC/Quitline
Description: Participants will be referred to local AHEC/Quitline for treatment
Study NCT04776785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont™ Repair
Description: It is a product used in biomimetic remineralization of initial carious lesions. The product consists of smart P11-4 peptide molecules (CUROLOX® TECHNOLOGY) that within the lesion the molecules self-assemble to a 3D matrix. This bio-matrix enables the regeneration of the tooth tissue.~Test 1 lesions will be cleaned with a prophylaxis paste and isolated with cotton rolls. Then, the pellicle will be removed using 2% sodium hypochlorite (20 sec) and the inorganic deposits will be removed using 35% phosphoric acid (20 sec). The tooth surface will be rinsed with water and dried. Thereafter, Curodont™ Repair will be applied in compliance with the manufacturers' instructions and left for 5 minutes.
Study NCT04776785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI Varnish™
Description: MI Varnish™ is a 5% sodium fluoride (NaF) varnish that has a desensitizing action when applied to tooth surfaces. The product also contains RECALDENT™ (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate. The application leaves a film of varnish on tooth surfaces and also facilitates the tooth remineralization.~Test 2 lesions will be isolated with cotton rolls. Then, MI Varnish ™ will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area.
Study NCT04776785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MI Varnish™
Description: MI Varnish™ is a 5% sodium fluoride (NaF) varnish that has a desensitizing action when applied to tooth surfaces. The product also contains RECALDENT™ (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate. The application leaves a film of varnish on tooth surfaces and also facilitates the tooth remineralization.~Test 2 lesions will be isolated with cotton rolls. Then, MI Varnish ™ will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area.
Study NCT04776785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profluorid® Varnish
Description: Profluorid® Varnish is a 5% sodium fluoride (NaF) varnish for surface application to enamel and dentin. The product will adhere to wet surfaces and is tolerant to moisture and saliva. Profluorid® Varnish is an ethanolic suspension of colophony with artificial flavors and sweetened with xylitol. It is also used in the remineralization of initial caries.~Control lesions will be isolated with cotton rolls. Then, Profluorid® Varnish will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area.
Study NCT04776785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profluorid® Varnish
Description: Profluorid® Varnish is a 5% sodium fluoride (NaF) varnish for surface application to enamel and dentin. The product will adhere to wet surfaces and is tolerant to moisture and saliva. Profluorid® Varnish is an ethanolic suspension of colophony with artificial flavors and sweetened with xylitol. It is also used in the remineralization of initial caries.~Control lesions will be isolated with cotton rolls. Then, Profluorid® Varnish will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area.
Study NCT02070796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR2.2.1
Description: Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours.
Study NCT02070796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine PR2.2.1
Description: Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours.
Study NCT02070796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR2.1.1
Description: Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours.
Study NCT02070796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine PR2.1.1
Description: Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours.
Study NCT04206579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Dextrose
Description: A mixture of 150 cc dextrose 10% in oral formulation
Study NCT04206579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrium Dextrose
Description: A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
Study NCT00372385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: tablet
Study NCT00372385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet
Study NCT00372385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection
Study NCT00372385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection
Study NCT00372385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study NCT00372385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: tablet
Study NCT03032471 — intervention group
Intervention type: OTHER
Intervention: There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
Description: There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
Study NCT00302627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: 60mg or 90mg given at baseline, 6,12,18, and 24 months
Study NCT00302627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: baseline, 6,12 months
Study NCT00302627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: baseline, 6,12 months
Study NCT05691556 — intervention group
Intervention type: PROCEDURE
Intervention: HABIT ILE rehabilitation course
Description: The HABIT-ILE course, created by the Belgian team of Prof. Yannick Bleyenheuft, is a rehabilitation of the upper and lower limbs, following the concepts of structured motor learning and intensive therapy. The internships last 2 weeks and are performed on a multi-year basis since 2018 at the SSR pediatric, Fondation Ildys, Site de Ty Yann in Brest.~In this group, upper limb assessments are performed the week before and the week after the HABIT ILE training course
Study NCT05691556 — intervention group
Intervention type: PROCEDURE
Intervention: botulinum toxin injections
Description: Toxin injections are used for their effect on the local reduction of spasticity after intramuscular injection. This treatment is usually offered to these children every 6 months or so for functional improvement.~These botulinum toxin injections are organized on a weekly basis in a pediatric day hospital (CHU Morvan in Brest).~In this group, upper limb assessments were performed 0-2 weeks before and then 4 to 6 weeks after the botulinum toxin injections (see table below), at the peak of the toxin's efficacy.
Study NCT03559478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sharp dissection with scalpel plus electrocautery to vessels
Description: A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
Study NCT03559478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery for all dissection
Description: Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
Study NCT02032303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of coronary flow reserve
Study NCT02032303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Study NCT02032303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor loading
Study NCT02032303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel loading
Study NCT01405937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir
Description: vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
Study NCT01405937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peg-IFN
Description: peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
Study NCT01405937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
Study NCT02949089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH04
Description: The subjects will receive the study medication in each group
Study NCT03067012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncometabolic reconstruction
Description: The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
Study NCT01541553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area
Study NCT01541553 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy
Description: Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area
Study NCT01541553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Field treatment with vehicle gel once daily for 3 consecutive days.
Study NCT01541553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol metabute
Description: Field treatment with vehicle gel once daily for 3 consecutive days.
Study NCT02939248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed ticagrelor followed by morphine
Description: Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
Study NCT02939248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed ticagrelor, morphine,naloxone
Description: Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
Study NCT02105350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK 162
Study NCT02105350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02105350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin